Patterns of medication use during pregnancy in rheumatoid arthritis
Authors:
Open Access
- 4 January 2011
- journal article
- research article
- Published by Wiley in Arthritis Care & Research
- Vol. 63 (5) , 721-728
Abstract
Objective: To characterize therapies prescribed during pregnancy to women with rheumatoid arthritis (RA).Methods: We conducted a cohort study of women with RA with pregnancies using health care utilization data from 2002–2008. We examined the distribution of RA drugs by therapeutic classes, including nonsteroidal antiinflammatory drugs (NSAIDs)/coxibs, glucocorticoids, nonbiologic disease‐modifying antirheumatic drugs (DMARDs), and biologic DMARDs, during 90‐day pregnancy trimesters and the 180 days prior to pregnancy. Drugs were characterized according to the Food and Drug Administration risk classification system. Differences in exposure by period were determined by chi‐square tests.Results: A total of 393 pregnancies were identified among 34,169 women with RA. Seventy‐two percent of pregnancies ended in a delivery. Approximately 24% of women with RA received a DMARD during preconception. At any point during pregnancy, 23% of women with deliveries were dispensed ≥1 DMARD and the proportion of use declined from the first to the third trimester (P = 0.03). Similar to DMARD therapy, use of NSAIDs/coxibs and exposure to category D/X medications were significantly lower compared to prepregnancy use (P < 0.05). In contrast, more women were prescribed glucocorticoids during pregnancy than before pregnancy. Use of biologics occurred in 12.5% of pregnancies. Compared to women with deliveries, women who experienced abortions were more frequently exposed to NSAIDs/coxibs (P < 0.05). Dispensing of category D/X medications was also higher in women with spontaneous abortions and primarily involved methotrexate (P < 0.05).Conclusion: Approximately 24% of women with RA received a DMARD in the 180 days before conception, and the proportion dropped during pregnancy. Glucocorticoid use remained high throughout pregnancy. Our results suggest that continued efforts directed at counseling women and their physicians about the potential risks/benefits of RA therapies during pregnancy are warranted.Keywords
This publication has 22 references indexed in Scilit:
- The implications of autoimmunity and pregnancyJournal of Autoimmunity, 2010
- Birth outcomes in women who have taken leflunomide during pregnancyArthritis & Rheumatism, 2010
- The management of rheumatic diseases in pregnancyScandinavian Journal of Rheumatology, 2010
- Postpartum onset of rheumatoid arthritis and other chronic arthritides: results from a patient register linked to a medical birth registryAnnals of the Rheumatic Diseases, 2010
- Management of RA medications in pregnant patientsNature Reviews Rheumatology, 2009
- Pharmacovigilance in pregnancy using population‐based linked datasetsPharmacoepidemiology and Drug Safety, 2009
- The remission of rheumatoid arthritis during pregnancySeminars in Immunopathology, 2007
- Pregnancy outcome in women who were exposed to anti–tumor necrosis factor agents: Results from a national population registerArthritis & Rheumatism, 2006
- Outcome of Pregnancy in Women Receiving Infliximab for the Treatment of Crohn's Disease and Rheumatoid ArthritisAmerican Journal of Gastroenterology, 2004
- Timing of Pregnancy in Relation to the Onset of Rheumatoid ArthritisArthritis & Rheumatism, 1992